A Landscape of Therapeutic Cooperativity in KRAS Mutant Cancers Reveals Principles for Controlling Tumor EvolutionGrace R. Anderson, Kris C. Wood, Jim C. Leeds et al.|Cell Reports|2017Cited by 86
Soft Tissue Sarcoma of the Extremities: What Is the Value of Treating at High-volume Centers?Alexander L. Lazarides, William C. Eward, David L. Kerr et al.|Clinical Orthopaedics and Related Research|2018Cited by 68
<i>PIK3CA</i> mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translationGrace R. Anderson, Kris C. Wood, Suzanne E. Wardell et al.|Science Translational Medicine|2016Cited by 58
Mediator kinase inhibition impedes transcriptional plasticity and prevents resistance to ERK/MAPK-targeted therapy in KRAS-mutant cancersDaniel P. Nussbaum, Kris C. Wood, Colin A. Martz et al.|npj Precision Oncology|2024Cited by 6
Abstract 5465: Systematic interrogation of druggable pathways in pancreatic adenocarcinomas using pooled gene-knockdown lentiviral librariesEdgar Ferrer-Lorenzo, Kris C. Wood, Daniel P. Nussbaum et al.|Cancer Research|2015Cited by 1